Reviva Pharmaceuticals News

Reviva to Participate in the BIO International Convention

CUPERTINO, Calif., May 21, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unm

Reviva PharmaceuticalsMay 21 00:00 ET

Maxim Group Remains a Buy on Reviva Pharmaceuticals Holdings (RVPH)

TipRanksMay 16 15:35 ET

Express News | Reviva Pharmaceuticals Holdings, Inc. : Maxim Group Cuts Target Price to $6 From $18

ReutersMay 16 00:02 ET

Reviva Pharmaceuticals Progresses With Global Schizophrenia Trial

TipRanksMay 15 08:22 ET

Express News | Reviva Pharmaceuticals Holdings, Inc. -Topline Data From 1-Year Open-Label Extension (Ole) Trial Expected in Q4 2024

ReutersMay 15 08:03 ET

Express News | Reviva Pharmaceuticals Holdings, Inc. -358 Enrolled and 223 Patients Currently on Treatment Across Sites in USA, Europe and Asia

ReutersMay 15 08:03 ET

Express News | Reviva Pharmaceuticals Holdings, Inc. -Brilaroxazine Is Generally Well Tolerated to Date in Patients With Acute and Stable Schizophrenia

ReutersMay 15 08:03 ET

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

– 358 enrolled and 223 patients currently on treatment across sites in the USA, Europe and Asia –– Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia ––

Reviva PharmaceuticalsMay 15 00:00 ET

Reviva Pharmaceuticals Operational Performance Insights

TipRanksMay 14 08:22 ET

10-Q: Quarterly report

SEC announcementMay 14 08:14 ET · Announcements

Reviva Pharm Holdings 1Q Loss/Shr 25c >RVPH

Reviva Pharm Holdings 1Q Loss/Shr 25c >RVPH

Dow JonesMay 14 08:04 ET

Express News | Reviva Pharmaceuticals Q1 Net Income USD -7.4 Million

ReutersMay 14 08:00 ET

Express News | Reviva Pharmaceuticals Q1 EPS USD -0.25

ReutersMay 14 08:00 ET

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia –– Registrational RECOVER-2 trial expected t

Reviva PharmaceuticalsMay 14 00:00 ET

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

CUPERTINO, Calif., May 13, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unm

Reviva PharmaceuticalsMay 13 00:00 ET

12 Health Care Stocks Moving In Thursday's Intraday Session

GainersEmbecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out to

BenzingaMay 9 12:31 ET

Press Release: Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDA

Dow JonesMay 9 08:00 ET

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

CUPERTINO, Calif., May 09, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unm

Reviva PharmaceuticalsMay 9 00:00 ET

Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)

TipRanksApr 22 06:20 ET

Express News | HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $20 Price Target

Moomoo 24/7Apr 22 06:15 ET